BioSpace News Archive

ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr. Emmanuelle Charpentier, announced it has signed an agreement with Applied StemCell, Inc., a leading provider of stem cell, animal model, antibody discovery services and reagents.

Troy Polan, acting CEO and Chief Technology Officer at Excelera, to share expertise on next-generation data analytics across a network of health system-based specialty pharmacies [15-September-2020] MINNEAPOLIS , Sept. 15, 2020 /PRNewswire/ -- Excelera ® , the company behind the Excelera Network, announced today that Troy Polan , acting CEO and Chief Technology Off

Amazon more than doubling reach of its childhood-to-career computer science education program – Amazon Future Engineer – extending program to over 3,000 more schools

DAVITA INC. announced the preliminary results of its modified “Dutch auction” tender offer for up to $1.0 billion of its common stock at a price per share of not less than $77.00 and not more than $88.00, which expired at 12:00 midnight, New York City time, at the end of the day on September 14, 2020.

Aerie Pharmaceuticals, Inc. announced that its sterile fill production facility in Athlone, Ireland has received approval from the U.S. Food and Drug Administration for production of Rhopressa® 0.02% for commercial distribution in the United States.

Plus Therapeutics, Inc., announced that the U.S. Food and Drug Administration has granted the Company Fast Track designation for its lead investigational drug, Rhenium NanoLiposomes, for the treatment of patients with recurrent glioblastoma.

Aravive, Inc., a clinical-stage oncology company developing transformative therapeutics, announced the appointment of industry veteran and oncologist, Reshma Rangwala, M.D., Ph.D., as Chief Medical Officer.

Apellis Pharmaceuticals, Inc. announced that the company has submitted a New Drug Application to the U.S. Food and Drug Administration and a Marketing Authorization Application to the European Medicines Agency for pegcetacoplan for the treatment of paroxysmal nocturnal hemoglobinuria in the United States and European Union, respectively.

AnPac Bio-Medical Science Co., Ltd. announced that the Company entered into a noteworthy sales contract in mid-August 2020 with Beijing Yuan Jian Health Management Co., Ltd. in China for the Company’s newly launched immunology test, AnPac Defense Medical Examination.

According to Transparency Market Research’s latest report on the global High Potency Active Pharmaceutical Ingredients market for the historical period 2017–2018 and forecast period 2019–2027, growing preference for outsourcing of HPAPI manufacturing and rich pipeline with targeted therapeutic drugs are the factors likely to boost the growth of High Potency Active Pharmaceutical Ingredients market.